Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 1.00 |
| ▸ | CTSD | P07339 | 18/20 | 1.00 |
| ▸ | BACE2 | Q9Y5Z0 | 16/20 | 1.00 |
| ▸ | REN | P00797 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061968 | 0.86 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4060868 | 0.85 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4064492 | 0.85 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4060360 | 0.85 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4062995 | 0.84 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL2793832 | 0.83 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4069535 | 0.83 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL4069532 | 0.83 | BACE1 (1.00) | BACE1CTSDBACE2REN | |
| SCHEMBL3531248 | 0.82 | BACE1 (0.82) | BACE1CTSDBACE2REN | |
| SCHEMBL3541409 | 0.82 | BACE1 (1.00) | BACE1CTSDBACE2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | claimed |
| EP-1758907-B1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | WYETH CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-7456186-B2 | Diphenylimidazopyrimidines as inhibitors of β-secretase | WYETH (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456186-B2 | Diphenylimidazopyrimidines as inhibitors of β-secretase | WYETH (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456186-B2 | Diphenylimidazopyrimidines as inhibitors of β-secretase | WYETH (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1758907-A1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | Wyeth (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006009655-A1 | DIPHENYLIMIDAZOPYRIMIDINE AND -IMIDAZOLE AMINES AS INHIBITORS OF B-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282826-A1 | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042912-A1 | DIPHENYLIMIDAZOLYL COMPOUNDS AS INHIBITORS OF beta-SECRETASE | BACE1, BACE2, APP | BACE1 1/4885CTSD 65/4885BACE2 2/4885 |
| US-20050282826-A1 | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase | BACE1, BACE2, APP | BACE1 1/4885CTSD 143/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.